Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB
about
Exploiting inflammation for therapeutic gain in pancreatic cancerInflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple OpponentsInflammation to cancer: The molecular biology in the pancreas (Review).IL-1α expression in pancreatic ductal adenocarcinoma affects the tumor cell migration and is regulated by the p38MAPK signaling pathway.Modulation of pancreatic cancer chemoresistance by inhibition of TAK1Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA.The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival.Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma.Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatmentExpression of IL-1α correlates with distant metastasis in patients with head and neck squamous cell carcinoma.Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-κB pathway dependent repression of PP2Ac.Profile of MMP and TIMP Expression in Human Pancreatic Stellate Cells: Regulation by IL-1α and TGFβ and Implications for Migration of Pancreatic Cancer Cells.Early onset pancreatic cancer: a controlled trial.Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression.Emerging pathways and future targets for the molecular therapy of pancreatic cancer.Multifaceted link between cancer and inflammation.NF-κB as a target for pancreatic cancer therapy.Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.The immune network in pancreatic cancer development and progression.B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells.Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts.Therapeutic potential of GW501516 and the role of Peroxisome proliferator-activated receptor β/δ and B-cell lymphoma 6 in inflammatory signaling in human pancreatic cancer cells.Sustained Inhibition of Proliferative Response After Transient FGF Stimulation Is Mediated by Interleukin 1 SignalingStructural basis for IL-1α recognition by a modified DNA aptamer that specifically inhibits IL-1α signaling.The TGFβ-SMAD3 pathway inhibits IL-1α induced interactions between human pancreatic stellate cells and pancreatic carcinoma cells and restricts cancer cell migration.Mast cell-derived TNF-α and histamine modify IL-6 and IL-8 expression and release from cutaneous tumor cells.SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.Tumor-stroma IL-1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer.NFκB-Mediated Invasiveness in CD133+ Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling.
P2860
Q27027661-0ADB590E-8517-4395-BA01-433AD69B2610Q33704284-80C2BAC4-2A15-483C-A5EE-B63E2F391E80Q33727657-D3551CD4-CF7E-44C9-9B0D-FD55C5374BDDQ34947925-6FFEFB6E-7BDD-4837-9C96-009CDC7503CBQ35143975-30D85E42-AD9F-4701-9CB7-5746AFAF512FQ35227104-364DA96D-234C-4FD6-A366-177D2E8E9C94Q35752182-CF26263B-4DE2-431D-A382-0F1CFB767035Q35809105-4C88225B-5D9E-464A-8D7D-885BC33E2FF8Q35820525-F8CC31B6-2464-455D-9E0E-FC03BDB8390DQ36070769-42EC16A3-5F5D-4C10-ACA0-CAF853711D3CQ36150219-0CB346D8-5DA0-40F7-AF8A-90B63562F565Q36545754-BAA85FBF-D015-4C3E-A526-7A1E271817A4Q37091930-D70027F3-31C5-4DD7-94F6-73ECEE10BF9FQ37112691-404B3BD9-78DD-472F-89EA-F48FD0618E63Q37647143-49829238-6A35-481B-B8FB-F3CA605E2E06Q37726658-613CCE81-9F87-460C-BA29-E83548E72295Q37912219-5944BF62-E946-4084-B2C6-480EF6CCEC7DQ37943405-3BDA4119-84D0-4AA3-8836-6FB65D3C8788Q37996435-7812842D-317C-4FC4-81E9-CF0B04732F4EQ38103859-2B2B9E10-EDAB-41D7-84B1-469395074D72Q38121412-2EB768BC-FF3B-4566-97A0-490F1A03FB6BQ39154102-E185C210-8A23-4E3B-8EA6-71B2FC86FC7FQ39489370-C1DF3C8F-1185-45E1-8312-BAD7155ED923Q41682512-BB33306B-22DF-4B82-B24A-71AE4E49B401Q41938265-66752841-50BB-47C1-A744-DDEFF9D46491Q42266398-9E7C1D99-54FD-44F2-B6D3-E157BF59BE18Q42393530-39318E18-D002-4C72-B6E9-68DA3B491A9DQ45882255-4DB1A5D3-D44E-4D88-89D4-3BBF5D7F1C38Q47616426-ABDBE96B-CA3B-4494-876E-E6A74D1B41C5Q49832519-3EF70CAB-9F4A-4120-B86F-880864A99787Q50262493-65E41F32-67C9-4C27-AABF-1F216B39DC42
P2860
Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Secreted interleukin-1alpha in ...... ation of nuclear factor-kappaB
@ast
Secreted interleukin-1alpha in ...... ation of nuclear factor-kappaB
@en
type
label
Secreted interleukin-1alpha in ...... ation of nuclear factor-kappaB
@ast
Secreted interleukin-1alpha in ...... ation of nuclear factor-kappaB
@en
prefLabel
Secreted interleukin-1alpha in ...... ation of nuclear factor-kappaB
@ast
Secreted interleukin-1alpha in ...... ation of nuclear factor-kappaB
@en
P2093
P2860
P1476
Secreted interleukin-1alpha in ...... ation of nuclear factor-kappaB
@en
P2093
Bailu Peng
Davide Melisi
Douglas B Evans
Jiangong Niu
Paul J Chiao
Qianghua Xia
Satoshi Ishiyama
P2860
P304
P356
10.1158/1541-7786.MCR-08-0201
P577
2009-05-12T00:00:00Z